Abstract
Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma.Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively.Results: 35.29% (6/17) of the patients were clinical benefit responders and 23.53% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29% (6/17)Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kozuch P, Petryk M, Evans A,et al. Therapy for regionally unresectable pancreatic cancer. Surg Clin North Am, 2001, 81: 691–697.
Burris HA, Moore MJ, Andersen J,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997, 15: 2403–2413.
Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer, 1997, 33: S18–22.
Burris H. Objective outcome measures of quality of life. Oncology (Huntingt), 1996, 10: 131–135.
Rothenberg ML, Moore MJ, Cripps MC,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol, 1996, 7: 347–353.
Fisher BJ, Perera FE, Kocha W,et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys, 1999, 45: 291–295.
Li JG, Jin HK, Touboul E. Simultaneous chemoradiotherapy for locally advanced pancreatic cancer. Chin J Radiat Oncol, 2001, 10: 232–235.
Azria D, Ychou M, Jacto W,et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cis-platin. Pancreas, 2002, 25: 360–365.
Peng LH, Xu J, Liu TF,et al. The clinical effect of intraoperative radiotherapy and gemcitabine for locally advanced pancreatic cancer. Chin J Cancer Prev Treat, 2002, 9: 323–324.
Unal AE, Bayar S, Serinsoz E,et al. Regional chemotherapyinduced cure for pancreatic head carcinoma. Hepatogastroenterology, 2002, 49: 556–557.
Ikeda M, Okada S, Tokuuye K,et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer, 2001, 91: 490–495.
Tsuruta K, Okamoto A, Egawa N,et al. Survival benefits of adjuvant chemotherapy with oral doxifluridine (5′-DFUR) following radiotherapy in patients with unresectable pancreatic cancer. J Surg Oncol, 2001, 78: 202–207.
Snady H, Bruckner H, Cooperman A,et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer, 2000, 89: 314–327.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huafeng, K., Xijing, W., Zhijun, D. et al. Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma. Chin. -Ger. J. Clin. Oncol. 2, 213–215 (2003). https://doi.org/10.1007/BF02835459
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02835459